Gennex Laboratories Limited (BOM:531739)
India · Delayed Price · Currency is INR 12.00
+1.18 (10.91%)
At close: Aug 17, 2026
Gennex Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,784 | 1,727 | 1,379 | 867.14 | 656.03 | 612.14 |
Other Revenue | -2.69 | - | -0 | - | - | - |
| 1,781 | 1,727 | 1,379 | 867.14 | 656.03 | 612.14 | |
Revenue Growth | 23.91% | 25.26% | 59.03% | 32.18% | 7.17% | 2.62% |
Cost of Revenue | 1,360 | 1,285 | 978.18 | 493.58 | 402.92 | 384.15 |
Gross Profit | 421.71 | 442.16 | 400.85 | 373.57 | 253.11 | 227.98 |
Selling, General & Admin | 73.24 | 80.39 | 88.01 | 78.91 | 80.63 | 73.48 |
Other Operating Expenses | 133.73 | 137.39 | 142.46 | 120.79 | 122.77 | 99.74 |
Operating Expenses | 234.1 | 244.26 | 250.37 | 223.38 | 212.6 | 181.1 |
Operating Income | 187.61 | 197.9 | 150.48 | 150.18 | 40.51 | 46.88 |
Interest Expense | -41.19 | -41.98 | -36.08 | -30.76 | -13.54 | -8.77 |
Interest & Investment Income | - | - | 95.71 | 37.95 | 26.61 | 9 |
Currency Exchange Gain (Loss) | - | - | 2.39 | 1.76 | 4.15 | 3.79 |
Other Non Operating Income (Expenses) | 82.46 | 82.46 | 1.68 | -0 | 5.5 | -0 |
EBT Excluding Unusual Items | 228.88 | 238.38 | 214.18 | 159.13 | 63.23 | 50.9 |
Gain (Loss) on Sale of Assets | - | - | -0.21 | 5.79 | 0.5 | 0.03 |
Pretax Income | 228.88 | 238.38 | 213.97 | 164.92 | 63.73 | 50.94 |
Income Tax Expense | 22.59 | 28.59 | 32.75 | 33.17 | 14.52 | 11.7 |
Net Income | 206.29 | 209.79 | 181.23 | 131.75 | 49.21 | 39.23 |
Net Income to Common | 206.29 | 209.79 | 181.23 | 131.75 | 49.21 | 39.23 |
Net Income Growth | 25.17% | 15.76% | 37.55% | 167.74% | 25.43% | -2.85% |
Shares Outstanding (Basic) | 278 | 275 | 227 | 187 | 146 | 127 |
Shares Outstanding (Diluted) | 278 | 275 | 231 | 217 | 154 | 127 |
Shares Change | 32.69% | 18.95% | 6.81% | 40.48% | 21.94% | - |
EPS (Basic) | 0.74 | 0.76 | 0.80 | 0.71 | 0.34 | 0.31 |
EPS (Diluted) | 0.74 | 0.76 | 0.78 | 0.61 | 0.32 | 0.31 |
EPS Growth | -5.67% | -2.68% | 28.78% | 90.60% | 2.86% | -2.78% |
Free Cash Flow | - | -755.91 | -197.44 | -466.86 | -161.1 | 103.14 |
Free Cash Flow Per Share | - | -2.75 | -0.85 | -2.15 | -1.04 | 0.81 |
Gross Margin | 23.67% | 25.60% | 29.07% | 43.08% | 38.58% | 37.24% |
Operating Margin | 10.53% | 11.46% | 10.91% | 17.32% | 6.17% | 7.66% |
Profit Margin | 11.58% | 12.14% | 13.14% | 15.19% | 7.50% | 6.41% |
Free Cash Flow Margin | - | -43.76% | -14.32% | -53.84% | -24.56% | 16.85% |
EBITDA | 215.73 | 224.38 | 170.38 | 173.86 | 49.7 | 54.76 |
EBITDA Margin | 12.11% | 12.99% | 12.35% | 20.05% | 7.58% | 8.95% |
D&A For EBITDA | 28.12 | 26.48 | 19.91 | 23.68 | 9.19 | 7.88 |
EBIT | 187.61 | 197.9 | 150.48 | 150.18 | 40.51 | 46.88 |
EBIT Margin | 10.53% | 11.46% | 10.91% | 17.32% | 6.17% | 7.66% |
Effective Tax Rate | 9.87% | 11.99% | 15.30% | 20.11% | 22.79% | 22.98% |
Revenue as Reported | 1,864 | 1,810 | 1,483 | 916.2 | 695.56 | 625.95 |